• SKIP TO CONTENT
  • SKIP NAVIGATION
  • Patient Resources
    • COVID-19 Patient Resource Center
    • Clinical Trials
    • Search Clinical Trials
    • Patient Notification System
    • What is Clinical Research?
    • Volunteering for a Clinical Trial
    • Understanding Informed Consent
    • Useful Resources
    • FDA Approved Drugs
  • Professional Resources
    • Research Center Profiles
    • Clinical Trial Listings
    • Market Research
    • FDA Approved Drugs
    • Training Guides
    • Books
    • eLearning
    • Events
    • Newsletters
    • JobWatch
    • White Papers
    • SOPs
    • eCFR and Guidances
  • White Papers
  • Trial Listings
  • Advertise
  • COVID-19
  • iConnect
  • Sign In
  • Create Account
  • Sign Out
  • My Account
Home » Almac launches next generation sequencing service for personalized medicine

Almac launches next generation sequencing service for personalized medicine

August 21, 2012
CenterWatch Staff

Global service provider Almac is launching a next generation sequencing (NGS) service to further expand its range of solutions supporting the development of personalized medicine.

The service is aimed to support Almac’s BioPharma partners in the development of molecular tests for trial enrichment and companion diagnostic development, specifically focusing on targeted re-sequencing. Almac previously launched a service focusing on the analysis of NGS data and based on feedback has decided to develop this service further to include data generation and to allow the delivery of NGS based assays in their CLIA lab.

Currently, Almac offers solutions using microarray, qPCR and IHC and the addition of the NGS platform fully complements this range of clinically focused diagnostic delivery platforms.

“There are only a limited number of platforms that are truly amenable to diagnostic delivery. The NGS field has now moved to a point where it is a viable delivery platform and as such is a logical addition to our suite of services,” said Paul Harkin, president and managing director of Almac’s diagnostics business unit. “We have already begun the process of developing CLIA based assays for important mutations involved in drug response.”

Almac already performs NGS for Omixon, a bioinformatics company focused on the development of validated data analysis solutions to scientists working in genomics.

“Almac complements our effort by providing the highest quality sequencing data. The MiSeq data we received from Almac is of highest quality which helped Omixon in developing and validating our HLA-typing software,” said Attila Bérces, founder and CEO of Omixon. “Next generation sequencing can revolutionize HLA-typing which is carried out on millions of samples annually.”

Upcoming Events

  • 25May

    2022 WCG Avoca Quality & Innovation Summit: Own the Future

  • 28Jun

    Effective Root Cause Analysis and CAPA Investigations for the Life Sciences

  • 16Oct

    WCG MAGI's Clinical Research Hybrid Conference - 2022 West

Featured Products

  • Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

    Spreadsheet Validation: Tools and Techniques to Make Data in Excel Compliant

  • Surviving an FDA GCP Inspection

    Surviving an FDA GCP Inspection: Resources for Investigators, Sponsors, CROs and IRBs

Featured Stories

  • Protocol-360x240.png

    Avoid Deviations by Making Protocol Review a Team Effort

  • SelectionProcess-360x240.png

    Give Us a Voice: Sites Clamor for a Say on Vendor Selection

  • Convince-360x240.png

    Use Data and Details to Convince Site Leadership to Add Staff

  • AsktheExpertsBadge-360x240.png

    Ask the Experts: Listing Trial Staff and Others on the Statement of Investigator

Standard Operating Procedures for Risk-Based Monitoring of Clinical Trials

The information you need to adapt your monitoring plan to changing times.

Learn More Here
  • About Us
  • Contact Us
  • Privacy Policy
  • Do Not Sell My Personal Information

Footer Logo

300 N. Washington St., Suite 200, Falls Church, VA 22046, USA

Phone 617.948.5100 – Toll free 866.219.3440

Copyright © 2022. All Rights Reserved. Design, CMS, Hosting & Web Development :: ePublishing